Form 4: Catalyst Pharmaceuticals Director Molly Harper Acquires Shares Through Vesting of Restricted Stock Units

Director Molly Harper of Catalyst Pharmaceuticals acquired 1,413 shares of common stock through the vesting of restricted stock units.

Summary

• Molly Harper, a director at Catalyst Pharmaceuticals, acquired 1,413 shares of common stock on December 9, 2024.
• This acquisition resulted from the vesting of restricted stock units.
• The restricted stock units vest in three equal tranches, with the first tranche vesting on December 8, 2024.
• The remaining tranches vest on December 8, 2025 and December 8, 2026.
• The shares were delivered to Ms. Harper on December 9, 2024.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed neutrally to slightly positive as it aligns director interests with shareholders.

Positives

• The vesting of restricted stock units aligns the director's interests with those of the shareholders.
• The acquisition of shares by a director can be seen as a positive sign of confidence in the company.

Industry Context

This is a routine filing related to the vesting of equity compensation for a company director, which is a common practice in publicly traded companies.

Comparison to Industry Standards

• The vesting of restricted stock units is a standard form of equity compensation for directors and executives in publicly traded companies.
• The vesting schedule of three equal tranches over three years is also a common practice to incentivize long-term performance and retention.

Stakeholder Impact

• The acquisition of shares by a director can be viewed positively by shareholders as it demonstrates confidence in the company's future.

Key Dates

Keywords

Catalyst Pharmaceuticals, Molly Harper, restricted stock units, share acquisition, director, vesting, insider trading